Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 15/20 | 0.56 |
| ▸ | DDB1 | Q16531 | 12/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.48 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.48 |
| ▸ | TTR | P02766 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA4 | P22748 | 1/20 | 0.47 |
| ▸ | CA6 | P23280 | 1/20 | 0.47 |
| ▸ | CA5A | P35218 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21554544 | 0.84 | CRBN (0.63) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL31274384 | 0.84 | CRBN (0.63) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL25873762 | 0.83 | CRBN (0.57) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL31273627 | 0.82 | CRBN (0.58) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL20501242 | 0.81 | CRBN (0.50) | CRBNDDB1IKZF3AKR1B10AKR1B1 | |
| SCHEMBL20501241 | 0.81 | CRBN (0.50) | CRBNDDB1IKZF3AKR1B10AKR1B1 | |
| SCHEMBL30990758 | 0.80 | CRBN (0.54) | CRBNDDB1ALDH1A1IKZF3AKR1B10 | |
| SCHEMBL27178599 | 0.78 | CRBN (0.57) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL27178601 | 0.78 | CRBN (0.57) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL30738830 | 0.78 | CRBN (0.63) | CRBNDDB1ALDH1A1CHRM2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322723-A1 | COMPOUNDS FOR SUPPRESSING EGFR MUTANT CANCER AND PHARMACEUTICAL USE THEREOF | J2H BIOTECH INC. (KR) | 2023-10-12 | — | — | US | disclosed |
| US-20230322723-A1 | COMPOUNDS FOR SUPPRESSING EGFR MUTANT CANCER AND PHARMACEUTICAL USE THEREOF | J2H BIOTECH INC. (KR) | 2023-10-12 | — | — | US | disclosed |
| US-20230322723-A1 | COMPOUNDS FOR SUPPRESSING EGFR MUTANT CANCER AND PHARMACEUTICAL USE THEREOF | J2H BIOTECH INC. (KR) | 2023-10-12 | — | — | US | disclosed |
| EP-4212522-A1 | COMPOUNDS FOR SUPPRESSING EGFR MUTANT CANCER AND PHARMACEUTICAL USE THEREOF | J2H Biotech Inc. (KR) | 2023-07-19 | — | — | EP | disclosed |
| EP-4212522-A1 | COMPOUNDS FOR SUPPRESSING EGFR MUTANT CANCER AND PHARMACEUTICAL USE THEREOF | J2H Biotech Inc. (KR) | 2023-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322723-A1 | COMPOUNDS FOR SUPPRESSING EGFR MUTANT CANCER AND PHARMACEUTICAL USE THEREOF | EGFR, KRAS, ERBB2 | CRBN 1013/4885DDB1 2612/4885ALDH1A1 2871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.